Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FTC distributes redress

This article was originally published in The Tan Sheet

Executive Summary

More than 5,700 consumers who bought dietary supplements and infrared saunas from Roex Inc. will receive checks averaging $500 from the Federal Trade Commission. The money, totaling $3 million, is redress from Roex for making alleged "bogus claims" that its products treat cancer, AIDs and other diseases, FTC said March 4. Roex, President Rodney Burreson and Mark Alexander, consumer education director, agreed in 2009 to pay the money to resolve false advertising allegations (1"The Tan Sheet" March 9, 2009, In Brief)

You may also be interested in...



Marketers pay $3 million fine

Dietary supplement marketing firm Roex Inc., and its president Rodney Burreson and director of consumer education Mark Alexander will pay $3 million in consumer redress to resolve Federal Trade Commission allegations they falsely advertised their supplements as treatment for cancer, AIDS, diabetes, Alzheimer's disease and other conditions. The settlement announced March 6 bars the marketers from making false claims about any drug, food, supplement or device and from misrepresenting tests and studies while advertising products or services

Big Pharma BD Execs Tell Start-Ups: Don’t Be Afraid To Ask Us For Help

Business development leaders and venture capital investors spoke at Biocom’s annual partnering conference about what they are seeking in relationships with entrepreneurs and start-ups.

Transformation Into Viatris Not Seen As The Solution Mylan Needs

Mylan’s full year 2019 earnings report was its last as an independent company, so the focus was on the coming merger with Pfizer’s Upjohn and growth prospects for the new company, Viatris.

Topics

UsernamePublicRestriction

Register

PS103891

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel